Literature DB >> 11419454

Patients, populations and policy: patient outcomes in chronic kidney disease.

N R Powe1.   

Abstract

Chronic kidney disease represents an interesting illustration for evaluating an epidemic of chronic illness, the impact of care processes and technology on health outcomes, the impact of financial incentives and cost containment on health outcomes, and the choices society must consider in responding to a chronic illness. The evidence suggests that strong economic pressures exist in the care of chronic kidney disease and that cost containment is important. The results in large part reflect the impact of economic pressures on clinical decision making in the absence of good evidence on outcomes. To improve clinical decision making we need valid evidence linking specific processes of care to patient outcomes. Specific processes amenable to study include the provision of preventive services, physician and nurse technical and interpersonal care and adherence to clinical practice guidelines. The ESRD Quality Study (EQUAL) currently underway and supported by the National Institutes of Diabetes and Digestive and Kidney Diseases, may help to guide physicians and centers in caring for their patients with chronic kidney disease. This investigation examines the relation between process of care and outcomes and expands outcomes measure to include disease-specific quality-of-life measures and patient satisfaction and accounts for case mix using the Index of Co-Existent Disease, a measure of the extent of different comorbid diseases as well as their severity (18,19,20). Better data on how processes of care are linked to health outcomes can inform decision making and allow educated cost cutting and quality maintenance.

Entities:  

Mesh:

Year:  2001        PMID: 11419454      PMCID: PMC2194417     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  16 in total

Review 1.  The quality of care. How can it be assessed?

Authors:  A Donabedian
Journal:  JAMA       Date:  1988 Sep 23-30       Impact factor: 56.272

2.  Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation.

Authors:  P P Garg; K D Frick; M Diener-West; N R Powe
Journal:  N Engl J Med       Date:  1999-11-25       Impact factor: 91.245

Review 3.  Prescription drugs in Medicare and the ESRD program.

Authors:  N R Powe
Journal:  Semin Nephrol       Date:  2000-11       Impact factor: 5.299

4.  For-profit versus not-for-profit dialysis care for children with end stage renal disease.

Authors:  S L Furth; W Hwang; A M Neu; B A Fivush; N R Powe
Journal:  Pediatrics       Date:  1999-09       Impact factor: 7.124

5.  Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.

Authors:  N R Powe; R I Griffiths; G F Anderson; G de Lissovoy; A J Watson; J W Greer; R J Herbert; P K Whelton
Journal:  Am J Kidney Dis       Date:  1993-10       Impact factor: 8.860

6.  Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.

Authors:  N R Powe; R I Griffiths; G de Lissovoy; G F Anderson; A J Watson; J W Greer; R J Herbert; P W Eggers; R A Milam; P K Whelton
Journal:  JAMA       Date:  1992-09-16       Impact factor: 56.272

7.  Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.

Authors:  N R Powe; R I Griffiths; E B Bass
Journal:  J Am Soc Nephrol       Date:  1993-04       Impact factor: 10.121

8.  The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors.

Authors:  F L Brancati; J C Whittle; P K Whelton; A J Seidler; M J Klag
Journal:  JAMA       Date:  1992-12-02       Impact factor: 56.272

9.  Early dosing practices and effectiveness of recombinant human erythropoietin.

Authors:  N R Powe; R I Griffiths; J W Greer; A J Watson; G F Anderson; G de Lissovoy; R J Herbert; P W Eggers; R A Milam; P K Whelton
Journal:  Kidney Int       Date:  1993-05       Impact factor: 10.612

10.  Implications for health care policy. A social and demographic profile of hemodialysis patients in the United States.

Authors:  R W Evans; C R Blagg; F A Bryan
Journal:  JAMA       Date:  1981-02-06       Impact factor: 56.272

View more
  1 in total

1.  Diabetes preventive services and policy implications in the U.S.

Authors:  Xiaoxing Z He
Journal:  Diabetes Care       Date:  2010-09-15       Impact factor: 19.112

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.